Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures

NCT01709110 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01709110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01709110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2012
Completion date
July 31, 2016
Enrollment
1,366 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis